Otsuka

News

Otsuka buys Jnana and PKU drug in $1.1bn deal

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketo

News

UK partnership aims to support NHS use of depression app

Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.

News

Four drugmakers found to have breached ABPI code

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceuti

R&D

3rd to 7th June – This week in clinical trials

In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.

Digital

Is digital therapeutics innovation enough for a sustainable ...

Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.

News

FDA clears first DTx for depression from Otsuka, Click

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.

Otsuka buys Jnana and PKU drug in $1.1bn deal

UK partnership aims to support NHS use of depression app

Four drugmakers found to have breached ABPI code

3rd to 7th June – This week in clinical trials

Is digital therapeutics innovation enough for a sustainable ...

FDA clears first DTx for depression from Otsuka, Click

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Otsuka

Editor's Picks